Cell3™ Target: Pan-Cancer (524) TMB/MSI Panel
Comprehensive analysis of cancer driver mutations in a single enrichment.
An NGS panel of 524 oncogenes that allows you to profile and stratify all common cancers and predict response to immunotherapy. All in one assay.
One workflow for multiple biomarkers
Detect cancer driver mutations across 524 oncogenes on all sample types in a single NGS enrichment. Less handling. Less time. More results first time.
Run ctDNA and FFPE samples
Validated on ctDNA and FFPE samples, as well as gDNA, giving you the option of profiling either primary or metastatic biopsies.
Measure tumor genomic instability
Confidently extrapolate tumor mutation burden (TMB) from panel sequencing data for immunotherapy response prediction.
An alternative to whole exome sequencing
Simplified analysis and reduced costs make this targeted panel an attractive alternative to whole exome sequencing (WES) for routine use.
If you have limited time and limited sample, targeted sequencing offers the best approach to profile common cancer genes via a comprehensive set of biomarkers in a single panel.
The Cell3™ Target: Pan-Cancer (524) TMB/MSI panel covers common driver mutations and allows the analysis of tumor mutation burden (TMB) and microsatellite instability (MSI) . This panel means you can process all of your oncology samples – regardless of sample type or tumor origin – in a single, simple workflow.
The Pan-Cancer (524) TMB/MSI panel covers 63 genes from NCCN/FDA cancer treatement guidelines, 116 cancer driver genes and 345 genes in vital cancer signalling pathways. The design, whilst exon focused, covers key intronic and promoter regions and contains a selection of CNV probes to support copy number calling across the genome. It is a comprehensive panel that allows you to accurately identify and profile variants associated with cancer and stratify all common cancers in a single workflow.
Predict a positive response to immunotherapy
TMB and MSI are biomarkers for immunotherapy response. Targeted sequencing offers a cost-effective way to measure them, but the size of a panel can influence the precision of their measurement. Too small and the measurement is imprecise (and therefore clinically suboptimal for patient stratification and response prediction) but too large and it is not cost effective for routine use. At 1.58Mb, the Nonacus Pan-Cancer (524) TMB/MSI panel, delivers accurate TMB estimation, cost effectively.
…in liquid biopsy and solid tumor samples.
With Cell3™ Target enrichment technology, this panel enables you to profile cancers from either circulating tumor DNA (ctDNA) or FFPE samples. This means you’re free to analyse liquid, primary or metastatic biopsies – all in one workflow.
Maximise sequencing efficiency
By increasing the yield per sample, Cell3™ Target libraries allow you to run more samples per flow cell, which increases your efficiency and reduces your cost per sample.
Detect low-level variants
The Cell3™ Target technology behind the Pan-Cancer panel incorporates error suppression technology, which includes unique molecular indexes (UMIs) and unique dual indexes (UDIs), to remove both PCR and sequencing errors and index hopping events. This allows confident and sensitive calling of mutations down to 0.1% VAF from as little as 10ng ctDNA input.
Product: Cell3TMTarget Pan-Cancer (524), Tumor Mutational Burden/MSI Panel, (16 samples)
Catalogue No.: C3299 (options A/B/C*)
Product: Cell3TMTarget Pan-Cancer (524), Tumor Mutational Burden/MSI Panel, (96 samples)
Catalogue No.: C3300 (options A/B/C*)
*All Cell3TM Target panels are available with three fragmentation options:
A = non-fragmentation e.g. cffDNA/ctDNA,
B = fragmentation e.g. gDNA or FFPE,
C = Both Fragmentation and Non-Fragmentation (half of each)
Detailed product information available to download.
If you have any questions about any of our products, including access to the BED files and example data sets, please fill in the support request form here[KNC1] and we will get back to you as soon as possible.
For Research Use Only. Not for use in diagnostic procedures.